Inovio readies early-2027 launch of DNA therapy for rare airway disease after FDA nod
Inovio expects first shipments of VOCERYQ about 60 days after its US clearance and a full launch in Q1 2027, with a European filing planned by year-end.
Inovio Pharmaceuticals has set out a commercial timetable for VOCERYQ after US regulators cleared it on 30 October 2026. The company expects orders to start shipping roughly 60 days after the clearance, with a full launch in the first quarter of 2027. It disclosed the approval alongside its third-quarter 2026 results.
VOCERYQ is given with Inovio's CELLECTRA 5PSP device and is indicated to cut the number of operations needed by adults with recurrent respiratory papillomatosis, a rare disease of the airway. Inovio describes the product as the first DNA medicine to win approval. That is the company's characterisation, not an independent finding.
The clearance came through the FDA's accelerated route, which allows earlier access in serious conditions on the strength of surrogate or intermediate evidence, in exchange for a confirmatory study. The decision rests on data from 32 patients. Inovio says it intends to run such a trial and expects to send a draft protocol to the agency by the end of 2026.
The company also plans to file a conditional marketing authorisation application in Europe before the end of 2026. The information available to CompePharma did not include pricing, sales forecasts or manufacturing arrangements for the product and device.
Why it matters
- Inovio has put dates on the commercial path: shipments about 60 days after approval, full launch in Q1 2027.
- The confirmatory trial is the key regulatory milestone: a draft protocol is due at the FDA by end-2026, and the design will bear on the product's long-term standing.
- Because the medicine is paired with the CELLECTRA 5PSP device, supply, labelling and post-market oversight will involve both components.
- A European conditional filing is planned before end-2026, so a 32-patient dataset will soon face scrutiny outside the US.
Company's press release (SEC filing): Inovio Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativa
TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML
CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupus
